Fluvoxamine

Status
Phase 2
Condition
COVID-19
Intervention Type
Oral Drug
Funder Type
Organization | University

Drug Details

Fluvoxamine is an anti-depressant drug approved by the FDA for the treatment of obsessive-compulsive disorder. 

Study Purpose

The purpose of this research study is to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent more serious complications like shortness of breath. Fluvoxamine is an anti-depressant drug approved by the FDA for the treatment of obsessive-compulsive disorder. The use of fluvoxamine for the treatment of COVID-19 is considered investigational, which means the US Food and Drug Administration has not approved it for this use.

This study is fully-remote, which means that there is no face-to-face contact; study materials including study drug will be shipped to participants' houses. Only residents of Missouri and Illinois may participate.

This drug has no clinical trials actively recruiting patients at this time.

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >